Previous studies have shown that CXCL9 is a favourable prognostic biomarker in patients with solid malignancies and a predictor of better response to anti-PD-1 therapy, while its tumour-promoting effect has also been reported in diffuse large B-cell lymphoma (7–9). This evidence concerns the gene CXCL9 and neoplasm.